genengnews
Biologic drugs have dominated the biopharmaceutical market in recent years and show no signs of slowing. While there is no shortage of therapeutic targets for drug developers designing monoclonal antibodies (mAB), validating those targets for clinical efficacy in various disease models is growing increasingly difficult. Since IL-11 was recently identified as an essential cytokine for inflammation and fibrosis, Enleofen and Aldevron developed monoclonal anti-IL-11 and anti-IL11RA antibodies for the treatment of non-alcoholic steatohepatitis (NASH) and other conditions.
Watch Now
forensicmag
Learn about new approaches for more efficient analysis of skeletal remains in this webinar, part 5 of a 6-part series. Sheree Hughes from Sam Houston State University will present a comparison of different methods for DNA extraction from bone—with and without powdering, and with and without automation. Rachel Oefelein from DNA Labs International will share streamlined Rapid DNA protocols for analysis of human remains, enabling fast recovery of discriminating DNA profiles for time-sensitive investigations such as disaster victim identification (DVI).
Watch Now
Cell therapy products have amazing potential to treat a wide variety of diseases and vast numbers of patients globally. However, establishing a scalable manufacturing technology that can reliably reproduce the yield and quality of derived products generated from small-scale R&D methods at larger scales sufficient for commercial manufacturing can pose many challenges.
Watch Now
Labroots
Mammalian cell line generation is a rate-limiting step in early CMC development and there is a constant desire to increase throughput. The implementation of automation is one way to increase throughput. This webinar will address some factors to consider during the process of automating a manual workflow including details of culture vessel changes, liquid handling adaptation, and changes of the cell line developer’s job during the process. With an end result of increased throughput, automation potentially allows cell line development to begin prior to final molecule selection. This can remove cell line development off the critical path of CMC development.
Watch Now